Dokumendiregister | Ravimiamet |
Viit | MSO-13/811-1 |
Registreeritud | 18.02.2025 |
Sünkroonitud | 19.02.2025 |
Liik | Sissetulev kiri |
Funktsioon | MSO Meditsiiniseadmed |
Sari | MSO-13 Meditsiiniseadmete kliiniliste uuringute ja toimivusuuringute dokumendid (taotlused, load, muud teavitused ja kirjavahetus) |
Toimik | MSO-13/2025 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | Beacon Scientific Consulting |
Saabumis/saatmisviis | Beacon Scientific Consulting |
Vastutaja | Merili Saar-Abroi (RA, Meditsiiniseadmete osakond) |
Originaal | Ava uues aknas |
From: Emma Brown <[email protected]>
Sent: Wed, 05 Feb 2025 11:03:57 +0000
To: "[email protected]" <[email protected]>
Subject: ICF guidance for combined studies of IMP & IVD
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
From: Emma Brown <[email protected]>
Sent: Mon, 10 Feb 2025 10:58:52 +0000
To: RA MSO <[email protected]>
Subject: Re: ICF guidance for combined studies of IMP & IVD
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Dear Dr. Brown,
Thank You for Your enquiry.
In Estonia, we accept both the joint and separate ICF. However, we have had issues with joint ICF-s as study sponsors tend to focus heavily on the medicinal trial while leaving out imporant
details about the device study in a joint ICF. In case we find that the ICF and the patient information sheet does not emphasize the device study enough and we are hesitant about whether the patient is able to understand that they are included in not one,
but two studies, we will require updates to the ICF, which will then lead to substantial modifications of the medicinal trial, new ethics committee approvals etc.
We recommend to prepare separate ICF-s as this would ease the sponsors burden in case any updates are necessary for the ICF. With separate ICF-s, the sponsor does not have to submit the document again to medicinal trial CA and the ethics committee in case the
medicinal trial has already received a CA approval and a positive ethics committee opinion in case we require updates in the IVD study-s ICF. Additionally, this will ensure that the patient understands that they are included in two separate studies – a medicinal
trial and an IVD performance study.
In case of any further questions, please do not hesitate to contact us again.
All the best,
Merili Saar-Abroi on behalf of
Department of Medical Devices
State Agency of Medicines
1 Nooruse Street
50411 Tartu
Estonia
Phone: +372 737 4140
www.ravimiamet.ee
Saatja: Emma Brown <[email protected]>
Saatmisaeg: kolmapäev, 5. veebruar 2025 13:04
Adressaat: RA MSO <[email protected]>
Teema: ICF guidance for combined studies of IMP & IVD
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Dear Sir, Dear Madam,
Please forgive the unsolicited email. I am trying to compile information for different countries under IVDR on the requirements for ICF when the study is combined IMP and IVD.
To date – my experience is that different countries have different requirements for the ICF:
• ICF for IVD and IMP
• ate ICF for IVD and IMP
In order to reduce the burden of RFIs and the workload to both Ethics Committees and the Sponsor submitting the application under IVDR/CTR I’m collating the ICF requirements.
Please can you advise what is the position for Estonia on ICFs for combined studies?
Many thanks and best wishes,
Dr Emma Brown
Dr Emma Brown
The Bradfield Centre
184 Cambridge Science Park, Milton Road
Cambridgeshire, CB4 0GA
NOTICE: This message, including any attachments, is intended for the use of the party to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure. If you are not the intended recipient, any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender immediately by replying to this e-mail and delete the original and any copies of this message. It is the recipient's sole responsibility to ensure that this message and any attachments are virus-free.
From: RA MSO
Sent: Mon, 10 Feb 2025 07:37:02 +0000
To: 'Emma Brown' <[email protected]>
Cc: RA MSO <[email protected]>
Subject: Vs: ICF guidance for combined studies of IMP & IVD
Dear Dr. Brown,
Thank You for Your enquiry.
In Estonia, we accept both the joint and separate ICF. However, we have had issues with joint ICF-s as study sponsors tend to focus heavily on the medicinal trial while leaving out imporant details about the device study in a joint ICF. In case we find that the ICF and the patient information sheet does not emphasize the device study enough and we are hesitant about whether the patient is able to understand that they are included in not one, but two studies, we will require updates to the ICF, which will then lead to substantial modifications of the medicinal trial, new ethics committee approvals etc.
We recommend to prepare separate ICF-s as this would ease the sponsors burden in case any updates are necessary for the ICF. With separate ICF-s, the sponsor does not have to submit the document again to medicinal trial CA and the ethics committee in case the medicinal trial has already received a CA approval and a positive ethics committee opinion in case we require updates in the IVD study-s ICF. Additionally, this will ensure that the patient understands that they are included in two separate studies – a medicinal trial and an IVD performance study.
In case of any further questions, please do not hesitate to contact us again.
All the best,
Merili Saar-Abroi on behalf of
Department of Medical Devices
State Agency of Medicines
1 Nooruse Street
50411 Tartu
Estonia
Phone: +372 737 4140
www.ravimiamet.ee
Saatja: Emma Brown <[email protected]>
Saatmisaeg: kolmapäev, 5. veebruar 2025 13:04
Adressaat: RA MSO <[email protected]>
Teema: ICF guidance for combined studies of IMP & IVD
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Dear Sir, Dear Madam,
Please forgive the unsolicited email. I am trying to compile information for different countries under IVDR on the requirements for ICF when the study is combined IMP and IVD.
To date – my experience is that different countries have different requirements for the ICF:
• ICF for IVD and IMP
• ate ICF for IVD and IMP
In order to reduce the burden of RFIs and the workload to both Ethics Committees and the Sponsor submitting the application under IVDR/CTR I’m collating the ICF requirements.
Please can you advise what is the position for Estonia on ICFs for combined studies?
Many thanks and best wishes,
Dr Emma Brown
Dr Emma Brown
The Bradfield Centre
184 Cambridge Science Park, Milton Road
Cambridgeshire, CB4 0GA
NOTICE: This message, including any attachments, is intended for the use of the party to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure. If you are not the intended recipient, any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender immediately by replying to this e-mail and delete the original and any copies of this message. It is the recipient's sole responsibility to ensure that this message and any attachments are virus-free.
Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
---|---|---|---|---|---|---|
Küsimused | 18.02.2025 | 1 | MSO-13/811-2 | Väljaminev kiri | ra | Beacon Scientific Consulting |